Net sales during the financial year increased by 4 percent to SEK 3,953 million (3,797), of which organic growth amounted to 5 percent and acquired growth amounted to 1 percent. Currency fluctuations had a negative impact of 2 percent on net sales.

EBITA increased by 11 percent to SEK 495 million (445), corresponding to an EBITA margin of 12.5 percent (11.7).

In Labtech, demand for consumables and reagents remained good, while investments in certain larger instrument deals were more restrained in periods, particularly within academic research. During 2025, the business area continued to strengthen its position in prioritised segments such as gene sequencing, advanced molecular diagnostics, blood gas and immunology. Contracts won in public tenders and renewed agreements on improved terms contributed to both growth and margin improvements. At the same time, ongoing efficiency measures were implemented in the companies, including through the development of the service and sales organisations.

Medtech’s net sales during the financial year amounted to SEK 6,495 million (6,496). Organic growth was 2 percent and acquired growth amounted to 1 percent. Currency fluctuations had a negative impact of 3 percent on net sales.

Adjusted EBITA increased by 7 percent to SEK 805 million (752), corresponding to an EBITA margin of 12.4 percent (11.6). EBITA amounted to SEK 964 million (746), corresponding to an EBITA margin of 14.8 percent (11.5). EBITA for the financial year was positively affected by a divestment of operations of SEK 158 million, and EBITA in the preceding year by a remeasured contingent consideration and restructuring costs of a total of SEK 6 million.

The companies within Medtech performed well, with continued focus on selective, profitable growth and clear margin improvements. Demand for advanced products in, among other areas, orthopaedics, spinal surgery, interventional radiology, pain management and welfare technology was good, although capital investments in healthcare were more restrained in certain countries, primarily in the United Kingdom. The number of procedures performed was also negatively affected by staff shortages and strikes in parts of Europe. Work to streamline the product portfolios, phase out less profitable products and replace them with more advanced, high-margin products continued during the year. In Homecare, the long-term investments in welfare technology and digital solutions began to deliver clear results, with increased demand and gradually strengthened margins.